HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send as an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Watafiti na wajumbe wa CAB wakiwa kwenye maaandamano katika kuadhimisha siku ya Ufahamu wa Chanjo ya VVU Duniani.… https://t.co/c2yxq7sY2p
10hreplyretweetfavorite
NIMRMbeya Wananchi na wakazi wa Mbalizi wakiwa katika foleni ya kupatiwa huduma ya upimaji wa VVU kwa hiari. #HVAD @NIMRHQS,… https://t.co/V7pJc2fsDg
11hreplyretweetfavorite
NIMRMbeya Watafiti wakifanya upimaji kwa wananchi waliojitokeza katika siku ya Ufahamu wa Chanjo ya VVU Duniani. #HVADhttps://t.co/to1zoI07st
11hreplyretweetfavorite
NIMRMbeya Mambo yalivyokuwa kwenye maadhimisho ya siku ya Ufahamu wa Chanjo ya VVU Duniani (Video kwa hisani ya Mbeya Yetu Tv… https://t.co/OTwaZvODIE
11hreplyretweetfavorite
© 2017 NIMR - Mbeya Medical Research Center